Home
News
Create
Screeners
Insights
Indo Us Bio-Tech
104.
27
+0.16
(+0.15%)
Market Cap
₹209.08 Cr
PE Ratio
78.58
Industry
FMCG
Buy
Sell
Company Performance:
1D
+0.15%
1M
+3.25%
6M
-26.69%
1Y
-32.63%
5Y
-64.36%
View Company Insights
Latest news about Indo Us Bio-Tech
Indo US Bio-Tech Appoints Mrs. Hemanshi Darsh Soni as Independent Director
10 days ago
Indo US Bio-Tech Limited has appointed Mrs. Hemanshi Darsh Soni (DIN: 11659183) as Additional Director in Non-Executive Independent Director capacity for 5 years from 21.04.2026, subject to shareholder approval. She brings service sector experience in building high-performance teams and operational processes, with no relationships to existing directors and no other listed entity directorships. The appointment complies with SEBI regulations and strengthens board independence.
Indo US Bio-Tech Limited Announces Resignation of Independent Director Mrs. Nehaben Sachinbhai Patel
10 days ago
Indo Us Bio-Tech Limited Submits SEBI Compliance Certificate for FY2026
Apr 06, 2026
Indo Us Bio-Tech Limited Issues Clarification on Recent Stock Price Movement
Mar 11, 2026
Indo-US Agriseeds Limited Reduces Stake in Indo US Bio-Tech Limited Through Open Market Sale
Mar 05, 2026
More news about Indo Us Bio-Tech
12
Feb 26
Indo-US Agriseeds continues stake reduction with 75,000 share sale
Indo-US Agriseeds Limited has disclosed another share sale in Indo US Bio-Tech Limited, selling 75,000 equity shares through open market operations on February 11, 2026. This latest transaction reduced the company's shareholding from 19,44,569 shares (9.6976%) to 18,69,569 shares (9.3236%) of the total voting capital.
21
Jan 26
Indo US Bio-Tech Reports Q3 FY26 Results with Net Profit of ₹299.66 Lakhs
Indo US Bio-Tech Limited reported Q3 FY26 net profit of ₹299.66 lakhs, down 40.7% from ₹505.45 lakhs in Q3 FY25, while revenue declined marginally to ₹2,279.83 lakhs. Nine-month performance showed revenue growth of 19.8% to ₹8,441.44 lakhs, though net profit decreased 11.4% to ₹1,115.11 lakhs. The auditors expressed qualified opinion due to incomplete assessment of new Labour Codes impact.
29
Dec 25
Indo US Bio-Tech Receives ED Summons Under PMLA for Inquiry Purposes
Indo US Bio-Tech Limited has received summons from the Directorate of Enforcement (ED) under the Prevention of Money Laundering Act (PMLA), 2002. The summons, dated November 20, 2025, requires the company's Principal Officer to appear and produce specific information and documents for investigation. The company stated that no formal charges have been made and no immediate material impact on financial or operational activities is expected. The disclosure was made to stock exchanges on December 29, 2025, with the company acknowledging a delay in reporting due to internal review processes.
Indo Us Bio-Tech
104.
27
+
0.
16
(+
0.
15
%)
1 Year Returns:
-32.63%
Industry Peers
LT Foods
430.65
(+
1.
31
%)
KRBL
367.15
(-
0.
94
%)
Gujarat Ambuja Exports
155.75
(+
2.
87
%)
Kaveri Seed Company
965.35
(+
4.
28
%)
Trualt Bioenergy
492.45
(+
1.
32
%)
GRM Overseas
165.97
(+
0.
34
%)
Sanstar
90.09
(+
4.
38
%)
Chaman Lal Setia Exports
281.32
(-
0.
80
%)
Gulshan Polyols
181.16
(-
0.
43
%)
Avt Natural Products
69.30
(+
0.
14
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO